ClinicalTrials.Veeva

Menu
T

Toronto Memory Program | Toronto, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gantenerumab
LY3314814
Lanabecestat
LY3002813
Simufilam
Aducanumab
RPh201
Lecanemab
ABBV-8E12
Donanemab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 61 total trials

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Placebo
Drug: Prasinezumab

Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Al...

Enrolling
Alzheimer Disease
Dementia
Drug: MK-1167
Drug: Placebo

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Active, not recruiting
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080-matching placebo
Drug: BIIB080

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Active, not recruiting
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intra...

Active, not recruiting
Alzheimers Disease
Drug: Placebo
Drug: RO7126209

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Lilly logo
Roche logo
Biogen logo
AbbVie logo
AstraZeneca logo
C
Eisai logo
Genentech logo
Pfizer logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems